Lucid Diagnostics (id:6893 LUCD)
0.997 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 7:12:51 PM)
Exchange closed, opens in 14 hours 17 minutes
About Lucid Diagnostics
Market Capitalization 49.34M
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
| Headquarters (address) |
360 Madison Avenue New York 10017 NY United States |
| Phone | 917 813 1828 |
| Website | https://www.luciddx.com |
| Employees | 70 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | LUCD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.630 - 1.58 |
| Market Capitalization | 49.34M |
| P/E trailing | -0.794 |
| P/E forward | -1.45 |
| Price/Sale | 12.99 |
| Price/Book | 3.02 |
| Beta | 1.42 |
| EPS | -1.21 |
| EPS United States (ID:6, base:3395) | 24.30 |